Tech Company Financing Transactions

RHYTHM Health Funding Round

Deerfield Capital, MPM Capital and New Enterprise Associates invested in a $41 million funding round for RHYTHM Health. The financing was announced on 2/18/2017.

Transaction Overview

Company Name
Announced On
2/18/2017
Transaction Type
Venture Equity
Amount
$41,000,000
Round
Undisclosed
Proceeds Purpose
The company will use the proceeds to: -- advance setmelanotide (RM-493), a novel melanocortin-4 receptor (MC4R) agonist that targets the MC4 pathway, into Phase 3 clinical trials for pro-opiomelanocortin (POMC) and leptin receptor (LEPR) deficiency obesity, and -- expand Phase 2 clinical trials for the treatment of obesity caused by several additional rare genetic deficiencies in the MC4 pathway, a key biological pathway in humans that regulates energy expenditure, homeostasis, and appetite.

Company Information

Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
500 Boylston St. 11th Floor
Boston, MA 02116
USA
Email Address
Overview
Rhythm is a biopharmaceutical company focused on developing and commercializing peptide therapeutics for the treatment of rare genetic deficiencies that result in life-threatening metabolic disorders.
Profile
RHYTHM Health LinkedIn Company Profile
Social Media
RHYTHM Health Company Twitter Account
Company News
RHYTHM Health News
Facebook
RHYTHM Health on Facebook
YouTube
RHYTHM Health on YouTube

Management Team

Title
Name
Email & Social
Chief Executive Officer
Keith Gottesdiener
  Keith Gottesdiener LinkedIn Profile  Keith Gottesdiener Twitter Account  Keith Gottesdiener News  Keith Gottesdiener on Facebook
Chief Financial Officer
Hunter Smith
  Hunter Smith LinkedIn Profile  Hunter Smith Twitter Account  Hunter Smith News  Hunter Smith on Facebook
Chief Medical Officer
Fred Fiedorek
  Fred Fiedorek LinkedIn Profile  Fred Fiedorek Twitter Account  Fred Fiedorek News  Fred Fiedorek on Facebook
Chief Scientific Officer
Lex Ploeg
  Lex Ploeg LinkedIn Profile  Lex Ploeg Twitter Account  Lex Ploeg News  Lex Ploeg on Facebook
VP - Bus. Development
Nithya Desikan
  Nithya Desikan LinkedIn Profile  Nithya Desikan Twitter Account  Nithya Desikan News  Nithya Desikan on Facebook


 

 

Browse more venture capital transactions:

Prev: 2/18/2017: Enbala Power Networks venture capital transaction
Next: 2/18/2017: Thyrve Microbiome venture capital transaction

 

Share this article

 


Where The Data Comes From

Our team works diligently to report on tech company VC transactions. VC investment data records on this site come from company press releases and news coverage. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.

 


Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary